Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma
W Sieghart, M Pinter, B Dauser, N Rohr-Udilova… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: The combination of erlotinib with sorafenib is currently being
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a
preclinical model. METHODS: The Morris Hepatoma (MH) and HepG2 cells were treated in
vitro with sorafenib (1–10μM) and erlotinib (1–5μM) and evaluated for tumor cell viability,
apoptosis, and target regulation. Antiangiogenic effects were studied by measuring VEGF
levels, endothelial cell viability, apoptosis, migration, and the aortic ring assay. In vivo, MH …
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a
preclinical model. METHODS: The Morris Hepatoma (MH) and HepG2 cells were treated in
vitro with sorafenib (1–10μM) and erlotinib (1–5μM) and evaluated for tumor cell viability,
apoptosis, and target regulation. Antiangiogenic effects were studied by measuring VEGF
levels, endothelial cell viability, apoptosis, migration, and the aortic ring assay. In vivo, MH …
以上显示的是最相近的搜索结果。 查看全部搜索结果